Cardiorenal syndrome

Iranian Journal of Kidney Diseases

Volumn 3, Issue 2, 2009, Pages 61-70

  Mahapatra, Himanshu Sekhar ^a   Lalmalsawma, Robert ^a   Singh, Narendra Pal ^a   Kumar, Mahender ^a   Tiwari, Suresh Chandra ^b  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Heart failure; Hemodynamics; Renal insufficiency

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; IBOPAMINE; IONOTROPIC RECEPTOR AGONIST; LEVOSIMENDAN; LOOP DIURETIC AGENT; NESIRITIDE; NITRIC OXIDE; NORADRENALIN; PLACEBO; REACTIVE OXYGEN METABOLITE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASODILATOR AGENT;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERVOLEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW DRUG DOSE; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT INDICATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; DIURETICS; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; NATRIURETIC AGENTS; NITRIC OXIDE; PREVALENCE; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SYNDROME; ULTRAFILTRATION; VASODILATOR AGENTS;

EID: 67449156158     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 1997 Annual Data Reprt. Bethesda, MD. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney diseases; 1997 [cited 2003 Nov 9]. Available from: http://www.usrds.org/adr_1997.htm/.
2. Samak MJ, Leveyy AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69.
3. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-41.
4. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-804.
5. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113-9.
6. Rao V, Weisel RD, Buth KJ, et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. Circulation. 1997;96:II-38-43; discussion II-4-5.
7. Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003;42:1535-43.
8. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76-84.
9. Stevenson LW, Nohria A, Mielniczuk L. Torrent or torment from the tubules? Challenge of the cardiorenal connections. J Am Coll Cardiol. 2005;45:2004-7.
10. van Kimmenade RR, Januzzi JL, Jr., Baggish AL, et al. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol. 2006;48:1621-7.
11. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004;9:195-201.
12. Bongartz LG, Cramer MJ, Doevendens PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J. 2005;26:11-7.
13. Putten KV, Braam B, Jie KE, Gaillard CAJM. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008;4:47-57.
14. National Heart, Lung, and Blood Institute Working Group. Cardiorenai connections in beak and Cardiovascular disease. National Heart, Lung and Blood Institute; 2007 [cited 2007 Oct 31]. Available from http://www.nhlbi.nih.gov/meetings/Workshops/cardiorenal-hf-hd.html/.
15. Francis G. Acute decompensated heart failure: the cardiorenal syndrome. Cleve Clin J Med. 2006;73 Suppl 2:S8-13; discussion S30-3.
16. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527-39.
17. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Ciroulation. 2004;109:1004-9.
18. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-7.
19. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avom J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999;138:849-55.
20. Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest. 2006;36 Suppl 3:78-88.
21. Spanaus KS, Kronenberg F, Ritz E, et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem. 2007;53:1264-72.
22. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patents. Am Heart J. 2004;147:331-8.
23. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol. 2000;85:1110-3.
24. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13-25.
25. Shlipak MG, Massie BM. The Clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514-7.
26. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-9.
27. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-10.
28. Adams KF Jr, Fonarow GC, Emerman CL, et al; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16.
29. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
30. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 1998 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney diseases; 1998 [cited 2004 Jan 20]. Available from http://www.usrds.org/adr_1998.htm/.
31. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60-9.
32. Warren DJ, Ferris TF. Renin secretion in renal hypertension. Lancet. 1970;1:159-62.
33. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R117-24.
34. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Aced Sci U S A. 2002;99:9450-5.
35. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Amal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000;20:645-51.
36. Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear calls. Kidney Int. 2000;57:2285-98.
37. Converse RL, Jr., Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-8.
38. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987-94.
39. Katoh M, Egashira K, Usui M, et al. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res. 1998;83:743-51.
40. Felker GM, Adams KF, Jr., Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44:959-66.
41. Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ. Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol Regul Integr Comp Physiol. 1995;268:R896-901.
42. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138:917-24.
43. Leier CV. Renal roadblock in managing low output heart failure. Crit Care Med. 2004;32:1228-9.
44. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31-8.
45. Philbin EF, Cotto M, Rocco TA, Jr., Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol. 1997;80:519-22.
46. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138:285-90.
47. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22.
48. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patents with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
49. Geisberg C, Butler J. Addressing the challenges of cardiorenal syndrome. Cleve Clin J Med. 2006;73:485-91.
50. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393-401.
51. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153:98-104.
52. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition dn diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62.
53. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with revere heart failure and early mortality. J Am Coll Cardiol. 2003;41:2029-35.
54. Remuzzii G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 1990;38:384-94.
55. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448-56.
56. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131-40.
57. Chatterjee K, Parmley WW, Cohn JN, et al. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J. 1985;110:439-47.
58. [No authors listed]. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-40.
59. Mehta R, Feldman D. Acute decompensated heart failure: best evidence and current practice. Minerva Cardioangiol. 2005;53:537-47.
60. Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled cliniclal trial. J Am Coll Cardiol. 2007;50:1835-40.
61. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuratic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-9.
62. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does hot improve, renal function in patents with chronic heart failure and worsening serum creatinine. Circulation. 2004; 110: 1620-5.
63. Yancy CW, Krum H, Massie BM, et al. Safety ahd efficacy of out patient nesiritide in patients with advanced heart failure. Results of the serial infusion of nesiritide (FUSION-II) trial. Circ Heart Fail. 2008;1:9-16.
64. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2001;49:675-83.
65. Lehtonen L. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure. Curr Heart Fail Rep. 2004;1:136-44.
66. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2003;42:140-7.
67. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. Jama. 2004;291:1963-71.
68. Gottlieh SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348-53.
69. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant. 2003;2:ii2-6.
70. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176-85.
71. Jie KE, Verhaar MC, Cramer MJ, et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol. 2006;291:F932-44.